Dupuytren's Contracture (Early Stage)
Investigational use for early-stage Dupuytren's nodules; case-series evidence for nodule softening, not for established contracture.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for Dupuytren's contracture. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Two small case series describe softening of EARLY nodules (no improvement in established cord-related contracture); there are no randomized controlled trials. Evidence-based options for established contracture include needle aponeurotomy (percutaneous needling), intralesional collagenase clostridium histolyticum injection (FDA-approved as Xiaflex for adults with palpable cord and contracture), and limited fasciectomy (gold standard for severe disease). Leech therapy does NOT lyse mature collagen cords.
- Hauptrisiken
- Bleeding from bite sites on the palm for 6 to 24 hours after detachment
- Bruising and tenderness over the palm for 5 to 10 days
- Damage to the digital neurovascular bundle if placement is improperly over the flexor tendon
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Cosmetic visible scars at bite sites on the palm
- Delay of definitive collagenase injection or fasciectomy with progressive contracture
- Inability to address established cord-related contracture (leeches cannot lyse mature collagen)
- Wer dies nicht in Betracht ziehen sollte
- Patients with established contracture greater than 30 degrees (MP or PIP) — surgical or collagenase indication
- Patients with a positive Hueston tabletop test (cannot place palm flat)
- Patients with active palm infection
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not been evaluated by a hand surgeon
- Patients with rapid progression or aggressive Dupuytren's diathesis
- Was Sie Ihren Kliniker fragen sollten
- What is my contracture in degrees (MP and PIP), and what is my Hueston tabletop test result?
- Have I been evaluated by a hand surgeon, and am I a candidate for collagenase injection (Xiaflex)?
- Am I a candidate for needle aponeurotomy or limited fasciectomy?
- What is the natural history of my disease (Dupuytren's diathesis: bilateral, young onset, family history, ectopic disease)?
- What evidence supports leech therapy for Dupuytren's — and only for early nodules versus established cords?
- Where exactly will leeches be placed — over nodules and away from the flexor tendon course?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Wann dringende medizinische Versorgung suchen
- Sudden severe palm pain, swelling, or inability to flex / extend the finger (possible flexor tenosynovitis — surgical emergency)
- Spreading redness, warmth, pus, or red streaks on the palm (cellulitis)
- New numbness, coldness, or pallor of the finger
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is not FDA-cleared for Dupuytren's contracture.
- Case series of EARLY nodule softening do NOT establish efficacy for established contracture.
- Mechanism rationale (early antifibrotic effects) does NOT lyse mature collagen cords.
- Leech therapy is not a substitute for collagenase injection (Xiaflex), needle aponeurotomy, or fasciectomy when indicated.
- Established contracture causing functional limitation requires hand-surgical evaluation, NOT complementary therapy.
Sicherheits-Querverweise
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M72.0
- Safety tier
- low
Evidence Summary
No controlled clinical trial or credible case series of leech therapy for Dupuytren's disease has been published; there is no reliable evidence that it softens palmar nodules or alters disease course, and there is no basis to expect leeches to affect established collagen cords. Any proposed antifibrotic mechanism is speculative and unproven. For established contracture causing functional limitation, evidence-based treatment (collagenase clostridium histolyticum injection, needle aponeurotomy, or limited fasciectomy) is required. ASH position: any use of leech therapy for Dupuytren's disease is investigational and mechanistic only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Ahmed M et al. (2016), n=12
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Established contracture >30 degrees (surgical referral)
- Active palmar infection
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.